Introduction {#Sec1}
============

Gene therapy using transiently expressed non-integrative plasmid vectors is the ideal solution for many public health applications. For example, no current therapy for diabetic foot ulcers directly improves the biology of wound healing as would gene therapy using the hypoxia-inducible factor 1α (HIF-1α) master regulator of wound healing genes.^[@CR1]^ A topically delivered gene-based drug is ideal for such growth factor replacement therapies, as plasmid has a far longer duration of expression compared with rapidly degraded recombinant peptides.

Extensive research to improve plasmid delivery has resulted in advanced methods such as electroporation (EP)-facilitated uptake, which dramatically improves gene transfer compared with passive DNA uptake. Plasmid-directed gene expression is now reaching the efficacy barrier that, to date, has prevented commercialization of gene-based plasmids for human application.^[@CR2]^

Although plasmid delivery has been the focus of gene transfer research, complementary vector design innovations may also be applied to improve transgene expression. We previously reported the development of potent minimalized antibiotic-free (AF) mammalian expression vectors.^[@CR3]^ AF vectors are derivatives of the pDNAVACCUltra expression vectors,^[@CR4]^ which incorporate and express a 150 bp RNA-OUT antisense RNA that represses expression of a host strain chromosome-encoded counter-selectable marker (SacB-encoded levansucrase) that is toxic in the presence of sucrose ([Figure 1a](#Fig1){ref-type="fig"}). These sucrose selectable vectors combine AF selection with highly productive fermentation manufacturing (\>1 g l^−1^ plasmid DNA yields) and improved transgene expression levels compared with existing vectors.^[@CR3],\ [@CR5],\ [@CR6],\ [@CR7],\ [@CR8]^ These plasmids were designed to remove non-essential extraneous sequences ([Figure 1](#Fig1){ref-type="fig"}) and are minimalized FDA (Food and Drug Administration)-compliant^[@CR9]^ vectors for gene therapy or genetic immunization applications. These AF vectors are also compliant with European regulatory agency recommendations to eliminate antibiotic resistance markers from plasmid therapy vectors.^[@CR10]^Figure 1AF selection vectors: (**a**) RNA-OUT-mediated AF selection. Left: In a plasmid-free cell, levansucrase was expressed from a chromosomally integrated *SacB* gene, leading to cell death in the presence of sucrose. Right: RNA-OUT from the plasmid repressed translation of the *SacB* gene, achieving plasmid selection; (**b**) NTC8385 EGFP AF vector with RNA-OUT selectable marker and HTLV-I R transient expression enhancer; (**c**) NTC8485 EGFP AF vector, with transient expression enhancers HTLV-I R, VA1 and SV40 enhancer. Optimization of the SV40-CMV boundary (BE deletion) resulted in a vector, NTC8685, with further improved expression; (**d**) gWIZ EGFP kanR vector with locations of non-essential spacer and junk DNA (TN903 inverted repeat, polyC, polyG and ampR promoter), annotated. The basepairs 1--245 pUC19 region functioned to maintain an optimal junction between the CMV promoter and the prokaryotic backbone. This sequence was retained in the equivalent location (in the NTC8385 vector-UP) and was replaced by the SV40 enhancer in the NTC8485 and NTC8685 vectors. In these vectors, the 1--245 bp pUC19 region was moved and added as an extension to the pUC origin to add back a leading strand primosomal assembly site (PAS-BH) present in pBR322. This site was deleted when the pUC vector was created by imprecise deletion of the repressor of primer (ROP) gene.^[@CR6]^ NTC8485 and NTC8685 PAS-BH vectors had higher plasmid copy number and manufacturing yields than did NTC8385 or gWIZ.^[@CR6]^

Although individual expression-augmenting sequences have been identified, they have not been used combinatorially to improve vector performance. We report herein the incorporation of rationally designed additive combinations of expression enhancers into optimized minimalistic AF vectors to effect improved transgene expression. The resultant high-production-yield, minimal, AF mammalian expression vectors incorporate novel vector backbone functionalities that further improve plasmid-directed transgene expression after transient transfection (transient expression enhancers; TEE platform: [Figures 1b and c](#Fig1){ref-type="fig"}). The viral human T-lymphotropic virus type I (HTLV-I) R, adenoviral viral associated (VA) RNAI (VA1) and SV40 enhancers used in this study were derived from non-coding regions of the respective viruses and did not have significant sequence homology to the human genome. These studies demonstrate that dramatic increases in vector-directed transgene expression can be obtained through innovations in vector design.

Results {#Sec2}
=======

Vector design criteria {#Sec3}
----------------------

To reduce chances in chromosomal integration, sequences added to a plasmid to increase transgene expression should contain no significant homology to the human genome. This may be determined by BLAST search, specifying to search for short, nearly exact matches against the human genome.^[@CR5],\ [@CR11]^

Regions encoding antigenic peptides should also not be present in vector backbones. These include cryptic open reading frames (ORFs) in bacterial or eukaryotic sequences that may be expressed in eukaryotic cells to generate unwanted and potentially detrimental cytotoxic T-cell^[@CR12],\ [@CR13],\ [@CR14]^ or humoral responses. The removal of spacer and junk sequences and the use of RNA-based selectable markers to eliminate the kanamycin-resistant (kanR) ORF reduce this risk.

Minimalized vector design {#Sec4}
-------------------------

The NTC8385, NTC8485 ([Figures 1b and c](#Fig1){ref-type="fig"}) and NTC8685 vectors (NTC8485 incorporating the Boundary Element deletion; [Figure 1c](#Fig1){ref-type="fig"}) described herein are minimalized vectors that do not contain extraneous spacer or junk sequences. These vectors incorporate a short 140 bp RNA-based selection marker rather than an antibiotic resistance marker ([Figure 1a](#Fig1){ref-type="fig"}). This resulted in much higher vector potency through elimination of approximately 2 kb of DNA compared with the gWIZ (Genlantis, San Diego, CA, USA) vector, which includes the kanR gene and associated extraneous DNA including the transposon TN903 inverted repeat, the ampicillin resistance marker promoter and polyC and polyG tailing site cloning footprints ([Figure 1d](#Fig1){ref-type="fig"}).

3′ untranslated region (UTR): 3′ UTR ORFs are translated {#Sec5}
--------------------------------------------------------

Many DNA vaccine vectors contain a single copy of the human or woodchuck hepatitis B virus posttranscriptional regulatory element (PRE or WPRE) immediately downstream of the stop codon before the transcriptional terminator. This element is commonly used in retroviral and lentiviral vectors as an alternative to the lentiviral Rev-response element to direct export of unspliced full-length viral genomic mRNA. PRE elements are included in DNA vaccines to increase spliced mRNA nuclear export and transgene expression. However, hepatitis genomes are highly compacted such that this enhancer also encodes a 178 amino-acid fragment of the hepatitis C virus polymerase gene.^[@CR15]^ The PRE, by design, is within the eukaryotic expression cassette; this type of design is known to generate T cells reactive to major histocompatibility complex-I epitopes in a cryptic ORF.^[@CR13]^ Such antigenic regions might significantly alter immune responses in individuals with previous exposure and memory T cells reactive to hepatitis.

To assess this risk, we quantified the translation of a coding region inserted, in different reading frames, downstream of the transgene stop codon in a cytomegalovirus (CMV) promoter expression vector. A neomycin resistance gene (NeoR) without an upstream Kozak sequence was cloned downstream of an enhanced green fluorescent protein (EGFP) transgene in different configurations similar to that used with PREs. Quantifiable neoR translation products were present in all tested configurations, as was biologically active neoR protein after plasmid transfection into both HEK293 and CHO cell lines ([Supplementary Table S1](#MOESM13){ref-type="media"}). These results demonstrated that expression enhancers should ideally be non-coding regions and that cryptic ORFs present downstream of the transgene within the exported eukaryotic mRNA can be translated, even when the ORF is not in the same reading frame as the upstream transgene.

5′ UTR: HTLV-I R transient expression enhancer {#Sec6}
----------------------------------------------

Although a number of 5′ UTR sequences have been identified that can be used to increase transgene expression (for example, see^[@CR16]^), the HTLV-I R element is very potent. When cloned downstream of the transcription start site, HTLV-I R improved expression through a variety of promoters, including SV40^[@CR17]^ and CMV,^[@CR18]^ and improved transgene expression in non-human primates.^[@CR18]^ CMV-HTLV-I R promoter plasmid vectors were found to be safe for human vaccination in NIH Vaccine Research Center-sponsored clinical trials of HIV, Ebola and severe acute respiratory syndrome (SARS) DNA vaccines. The CMV-HTLV-I R promoter has HTLV-I R incorporated as part of exon 1 and intron 1 downstream of the CMV promoter ([Figure 1b](#Fig1){ref-type="fig"}). This configuration improved DNA vaccine expression and immunogenicity.^[@CR3],\ [@CR18]^ Incorporation of HTLV-I R into NTC8385 ([Figure 1b](#Fig1){ref-type="fig"}) dramatically increased transgene expression in HEK293 total cellular extracts ([Figure 2a](#Fig2){ref-type="fig"}) and fluorescence-activated cell sorting (FACS) sorted cells ([Figure 2b](#Fig2){ref-type="fig"}) after transient transfection. This was due to increased mRNA translation efficiency (that is, HTLV-I R increased the amount of EGFP transgene produced per pg cytoplasmic EGFP mRNA; [Figure 2c](#Fig2){ref-type="fig"}), but not due to increased overall cytoplasmic mRNA levels. By contrast, no effect on integrated expression (either total mean fluorescence or fluorescence per integrated transgene copy) was observed in HEK293 ([Figure 2d](#Fig2){ref-type="fig"}) or CHO-K1 ([Supplementary Figure S1](#MOESM13){ref-type="media"}) cells. Consistent with this, the cytoplasmic mRNA translational efficiency improvement observed with HTLV-I R from transiently transfected plasmid did not occur with cytoplasmic RNA produced from genomically integrated plasmid ([Figure 2c](#Fig2){ref-type="fig"}). Interestingly, the overall amount of EGFP transgene produced per pg of cytoplasmic EGFP mRNA was dramatically higher than that from genomically integrated plasmid compared with transiently transfected plasmid for both CMV and CMV-HTLV-I R promoter plasmids ([Figure 2c](#Fig2){ref-type="fig"}).Figure 2HTLV-I R is a transient expression enhancer. HEK293 cells were transfected in triplicate with CMV or CMV-HTLV-I R NTC8385 backbone vectors (supercoiled or linearized with *Dra*III; see [Figure 1b](#Fig1){ref-type="fig"}) expressing an EGFP-IRES-neo transgene ([Supplementary Table S1](#MOESM13){ref-type="media"}). At T=48 h post transfection, cells for FACS, cytoplasmic RNA for RT-PCR and extracts for EGFP fluorescence were prepared. Transfected cells were replated and stable integrants were selected by 10-day treatment with Geneticin. Samples for EGFP fluorescence were taken after 4, 12 and 24 generations propagation post selection (G4, G12, G24). Samples for (1) FACS; (2) genomic DNA isolation for RT-PCR-integrated plasmid copy number determination; and (3) cytoplasmic RNA for RT-PCR were taken at G4: (**a**) HTLV-I R increased transgene expression in transient transfection, but did not increase integrated gene expression. Total mean±s.d. fluorescence (FU) of EGFP extracts from the three transfections at the indicated time points is shown; (**b**) HTLV-I R affected transgene expression in individual cells rather than transfection efficiency. Total mean±s.d. fluorescence (FU) of transient and G4 cells after FACS is shown. The percentage of total cells gated (percentage of expressing cells) was equivalent between the CMV and CMV-HTLV-I R groups (transient: supercoiled 75--79%, linear 61--65%; G4: supercoiled 79--86%, linear 84--87%); (**c**) HTLV-I R increased mRNA translation after transient transfection. The amount of EGFP protein produced per unit EGFP cytoplasmic mRNA (EGFP FU/ (pg EGFP RNA/ng cytoplasmic mRNA)) pre- (T) and post integration (G4) is shown. (**d**) HTLV-I R did not increase transgene expression after genomic integration. Total mean±s.d. fluorescence of EGFP extracts from G4 integrated cell lines (FU) and FU per integrated transgene copy number per genome (FU/copy) are shown. Integrated copy number was determined using RT-PCR quantification of the EGFP transgene in isolated quantified genomic DNA.

The *in vivo* effect of the HTLV-I R region on plasmid vaccination was determined in rabbits. Immunization of rabbits with a CMV-HTLV-I R promoter HIV-1 gp120 DNA vaccine vector combined with EP delivery induced up to ½ log higher titers of HIV-1 virus-neutralizing antibodies (IC~50~) than a comparator CMV promoter vector ([Figure 3](#Fig3){ref-type="fig"}). Improved IC~50~ titers were observed with both neutralization-sensitive (NL4-3 and SF162) and -resistant (6535 and JRCSF) viruses. This is likely attributable to a higher gp120 expression with the CMV-HTLV-I R plasmid. These results demonstrate that this modified 5′ UTR vector design improved vector performance *in vivo* when combined with an optimal DNA delivery platform (EP).Figure 3Comparison of CMV and CMV-HTLV-I R promoter HIV-1 gp120 DNA vaccine vectors in inducing neutralizing antibodies. The gp120 viral envelope protein was expressed by either CMV promoter vector pMAmp (giving plasmid 1001) or AF, CMV-HTLV-I R promoter NTC8382 (8382). Neutralization activity on days 70 (2 weeks after the last of three DNA injections) and 98 (2 weeks after a gp120 protein boost) to four HIV-1 strains was determined. The *y* axis shows the log10 transformation of the half-maximal inhibitory concentration (IC~50~) of neutralizing antibody titers (higher numbers represent stronger neutralization). Neutralization was tested on two neutralization-sensitive viruses (**a**) NL4-3 and (**b**) SF162 and on two resistant viruses (**c**) 6535 and (**d**) JRCSF.

Protein kinase regulated by RNA (PKR) inhibitor: VA1 transient expression enhancer {#Sec7}
----------------------------------------------------------------------------------

Activation of PKR inhibits mRNA translation through eukaryotic initiation factor-2α phosphorylation.^[@CR19],\ [@CR20]^ PKR is activated either by its ligand, double-stranded RNA or by the PKR-associated activator protein (PACT, and in murine cells by the RAX ortholog) in response to diverse non-nucleic acid-based cell stresses including endoplasmic reticulum stress (the unfolded protein response).^[@CR21]^ Cell stress is induced by certain plasmid deliveries (for example, liposomal or calcium phosphate formulations) and/or by expression of aggregation-prone proteins (for example, hydrophobic membrane-domain-containing proteins, polyepitope synthetic proteins). Therefore, inclusion of a PKR inhibitor in the vector backbone may improve plasmid-mediated expression under stress conditions.

The adenovirus serotype 5 VA RNAI (VA1) and the Epstein--Barr Virus EBER1 RNAs are non-coding RNA Pol III-expressed small RNA-based PKR inhibitors. VA RNAI was included in the pAdVAntage Vector (Promega, Madison, WI, USA) plasmid backbone to increase target gene expression of co-transfected plasmids.^[@CR22]^ For human vaccination, VA RNAI is preferable to EBER1, as EBER1 binds multiple cellular proteins and has documented cell growth-stimulating properties. These adverse properties have not been attributed to VA1, and, as a natural adenovirus gene, VA1 is present in multiple adenoviral vectors evaluated in human clinical trials.

CMV-HTLV-I R promoter plasmids encoding VA1 (for example, NTC8385-VA1-EGFP; [Figure 1b](#Fig1){ref-type="fig"}) had increased transgene expression compared with the parent CMV-HTLV-I R promoter vector after transient expression of human HEK293 cells ([Figure 4b](#Fig4){ref-type="fig"}). CMV-HTLV-I R- and CMV promoter-directed transgene expression levels were not affected by addition of RNA Pol III inhibitor to the transfection (RNA Pol III independent; [Figure 4a](#Fig4){ref-type="fig"}). In contrast, as expected, VA1-mediated increased transgene expression was RNA Pol III dependent, as it was inhibited at all tested RNA Pol III inhibitor concentrations ([Figure 4b](#Fig4){ref-type="fig"}). VA1 increased transiently transfected mRNA translation efficiency (EGFP transgene produced per pg of cytoplasmic EGFP mRNA; [Supplementary Figure S2](#MOESM13){ref-type="media"}), but had no effect on translation efficiency after forced integration in HEK293 cells (EGFP protein produced per integrated transgene; [Figure 4d](#Fig4){ref-type="fig"}). VA1- and HTLV-I R-directed transient expression enhancement was also observed in human A549 and murine NIH-3T3 and L929 cell lines ([Supplementary Figure S3](#MOESM13){ref-type="media"}). These results demonstrated that both HTLV-I R and VA1 increased translation of transiently expressed mRNAs and that their effects were not redundant. The variability in the activity of these elements between these cell lines probably reflected differences in levels of cellular cofactors required for VA1 and HTLV-I R activity.Figure 4VA1 is a transient expression enhancer: (**a**) Pol III transcription is dispensable for HTLV-I R-mediated expression enhancement. HEK293 cells were plated and pretreated 10 h with RNA Polymerase III inhibitor (Pol III inhibitor; EMD Biosciences Gibbstown, NJ, USA) at the indicated concentration, then transfected (Lipofectamine 2000) with EGFP plasmids containing the CMV or CMV-HTLV-I R promoter in the presence of Pol III inhibitor. Cell extract EGFP fluorescence (FU) was determined 40 h post transfection. Cell growth was inhibited with 20 μ[M]{.smallcaps} of Pol III inhibitor, which accounts for the observed reduced FU at this concentration; (**b**) Pol III transcription was required for VA1 expression enhancement effect. The assay was in the same format as in (**a**), except for the fact that Pol III inhibitor-treated cells were transfected with EGFP plasmids containing the CMV-HTLV-I R promoter with or without VA1; (**c**) Inhibition of PKR, not of adenosine deaminase acting on RNA (ADAR) or RNA interference (RNAI), was required for VA1 expression enhancement effect. HEK293 cells were transfected with NTC7485-EGFP (same backbone as NTC8485, except for kanR instead of RNA-OUT) and NTC7485-EGFP- modified to contain: VA1 (PKR+RNAI+ADAR+inhibitor); VA1-PKR3 (PKR−RNAI+ADAR?inhibitor), in which VA1 incorporated the L3 point mutation,^[@CR26]^ (the designation 'ADAR?' was used, as the effect of L3 on ADAR inhibition has not been established); or VA1-PKR5 (PKR−RNAI+ADAR+inhibitor) in which VA1 incorporated a 1 bp change (pm91) in the central domain.^[@CR27]^ (**d**) VA1 did not increase transgene expression after genomic integration. Postintegration expression of (1) kanR gWIZ (CMV) compared with (2) AF gWIZ derivative containing the CMV-HTLV-I R promoter (instead of CMV) and the VA1 gene (CMV/AF-HTLV-I-VA1). CHO cells were transfected with EGFP-IRES-neo transgene versions of both plasmids using lipofectamine LTX in quadruplicate (using four different ratios of plasmid to LTX). Integrants were selected with Geneticin for 10 days. Results presented are after nine generations post selection (G9). Total mean±s.d. fluorescence of EGFP extracts from four G9 integrated cell lines per vector (FU) and FU per integrated transgene copy number per genome (FU/copy) are shown. Integrated copy number was determined using RT-PCR quantification of the EGFP transgene in isolated quantified genomic DNA.

VA1-mediated PKR inhibition may account for increased transgene expression. Alternatively, PKR-independent stimulation of gene expression may be through VA1 inhibition of adenosine deaminase acting on RNA^[@CR23]^ or through RNA interference.^[@CR24],\ [@CR25]^ This was determined by testing the effects of function-specific point mutations in the vector-encoded *VA1* gene ([Figure 4c](#Fig4){ref-type="fig"}) on EGFP expression. VA1-PKR3 incorporated the L3 mutation. This is a 2 bp change in the central domain that has been shown to be inactive for PKR inhibition,^[@CR26]^ yet is transcribed at high level in cell culture and maintains the VA RNAI-like RNA secondary structure necessary for RNA interference inhibition. VA1-PKR5 incorporated a 1 bp change (pm91) in the central domain that is strongly reduced for PKR inhibition,^[@CR27]^ but retained adenosine deaminase acting on RNA-inhibiting activity^[@CR23]^ and the VA RNAI-like RNA secondary structure required for RNA interference inhibition. The results ([Figure 4c](#Fig4){ref-type="fig"}) suggest that PKR inhibition, and not adenosine deaminase acting on RNA or RNA interference inhibition, was critical for VA1-mediated transgene expression enhancement, as this effect was lost with both PKR3 and PKR5 point mutants.

Nuclear membrane transit: SV40 enhancer transient expression enhancer {#Sec8}
---------------------------------------------------------------------

Sequences that, when incorporated into a vector backbone, improve plasmid nuclear localization will also enhance non-viral gene expression, as DNA transport to the nucleus is a limiting factor in non-dividing cells (reviewed in Lam and Dean,^[@CR28]^ and Wagstaff and Jans^[@CR29]^). Such sequences would be true transient expression enhancers, as they function to enhance plasmid nuclear entry, not mRNA production or translation, which could also affect chromosomal gene expression. Mechanisms for sequence-specific plasmid DNA nuclear import are being delineated,^[@CR30]^ and a number of DNA transcription factor binding sites have been identified that increase plasmid nuclear import when added to a plasmid vector backbone.^[@CR28]^ Several of these were incorporated into the NTC8385-VA1 vector backbone and evaluated for improved expression.

### SV40 enhancer {#Sec9}

Inclusion of the SV40 72 bp enhancer upstream or downstream of the expression cassette in a DNA vaccine vector backbone increased *in vivo* expression up to 20-fold using EP delivery in muscle tissue.^[@CR31],\ [@CR32]^ This enhancement was not observed *in vitro*.^[@CR31]^ The NTC8485 vector ([Figure 1c](#Fig1){ref-type="fig"}) contains the SV40 enhancer (two copies of the 72 and the 21 bp repeats) ([Figure 5a](#Fig5){ref-type="fig"}). This enhancer region, as part of the SV40 promoter, has not caused safety concerns in human clinical trials of SV40 promoter-containing vectors. NTC8485 had improved manufacturing yields because of improved copy number mediated by the SV40 enhancer and the PAS-BH replication origin.^[@CR6]^ This configuration of the SV40 enhancer with the CMV promoter was also shown to improve transgene expression after EP-mediated delivery to murine muscle.^[@CR33]^ As expected, *in vitro* expression of NTC8485 was similar to the NTC8385 vector ([Figure 5b](#Fig5){ref-type="fig"}). Treatment with tumor necrosis factor-α, which induces nuclear localization of nuclear factor-κB (NF-κB), thereby increasing transgene expression by activation of multiple NF-κB sites in the CMV promoter, resulted in a higher expression than NTC8385 ([Figure 5b](#Fig5){ref-type="fig"}), perhaps through activation of the two NF-κB sites in the SV40 enhancer ([Figure 5a](#Fig5){ref-type="fig"}). Addition of three NF-κB binding sites to NTC8485 (NTC8485-κB) further improved expression after tumor necrosis factor-α activation ([Figure 5b](#Fig5){ref-type="fig"}).Figure 5SV40 enhancer-containing NTC8485 and NTC8685 vectors: (**a**) annotation of the SV40 enhancer (two copies of both the 72 and 21 bp repeats) in NTC8485. The NTC8685 deletion of the CMV upstream region (boundary element, BE) between the CMV enhancer and the SV40 enhancer is shown (BE (NTC8685)), as well as the location of a variety of transcription factor binding sites in the SV40 enhancer and CMV upstream region and enhancer.^[@CR34],\ [@CR35],\ [@CR36]^ (**b**) Average±s.d. of total fluorescence (EGFP expression) in the HEK293 cell line of CMV-HTLV-I R promoter vectors, with or without VA1 and SV40 enhancer (NTC8485 and NTC8685), compared with CMV promoter vector pVAX1. Cells were transfected for 3 h, and then incubated with tumor necrosis factor (TNF)-α, versus no TNFα control, for 3 h before addition of fresh medium overnight. EGFP expression was determined 21 h post transfection. (**c**) HEK293 cells were transfected in triplicate with the indicated EGFP plasmid (*dcm*−) and total cell EGFP fluorescence was determined 48 h post transfection. Average±s.d. of total fluorescence is shown; (**d**) HEK293 cells were transfected with *dcm*− plasmid as in (**c**), except that cells were growth arrested with aphidicolin before and during the transfection. Results without TNFα stimulation are shown; similar results were obtained with TNFα treatment post transfection. (**e**) A549 cells were transfected in triplicate with the indicated EGFP plasmid (*dcm*−) and total cell EGFP fluorescence was determined 24 h post transfection. Average±s.d. of total fluorescence is shown. Similar results were obtained with TNFα treatment for 3 h post transfection. (**f**) A549 cells were transfected as in (**e**), except that cells were growth arrested with aphidicolin before and during transfection. Results without TNFα stimulation are shown; similar results were obtained with 3 h TNFα treatment post transfection.

NTC8485 contains the AT-rich unique region upstream of the CMV enhancer. The unique region contains a boundary domain^[@CR34]^ and several binding sites for cellular repressor proteins PDX1^[@CR35]^ and CDP ([Figure 5a](#Fig5){ref-type="fig"}).^[@CR36]^ These sequences may interfere with SV40 enhancer interactions with the CMV promoter. Consistent with this, deletion of the unique region between the SV40 and CMV enhancer junction (to create NTC8685) increased transgene expression in dividing HEK293 cells compared with the NTC8485 parent vector ([Figures 5b and c](#Fig5){ref-type="fig"}). As the SV40 enhancer did not generally improve expression *in vitro*,^[@CR31]^ the unique region deletion in NTC8685 may allow SV40 enhancer-mediated activation of the CMV promoter. This optimized configuration had higher expression than NTC8485-κB, with and without tumor necrosis factor-α, and approximately 10-fold higher expression than the kanR pVAX1 (Invitrogen, Carlsbad, CA, USA) CMV promoter vector ([Figure 5b](#Fig5){ref-type="fig"}).

The SV40 enhancer NF-κB sites are substrates for the *E coli* dcm methylase that methylates the internal cytosine residues in the recognition sequence 5′-CC^\*^AGG-3′ or 5′-CC^\*^TGG-3′ to 5-methyl-cytosine (5mC). Methylation of these sites may reduce NF-κB binding and SV40 enhancer-mediated activation of the CMV promoter in the optimized NTC8685 vector. Consistent with this, NTC8685 plasmid produced in a *dcm*− host strain had much higher expression than *dcm*+plasmid ([Figure 5b](#Fig5){ref-type="fig"}).

Expression levels of NTC8385, NTC8485 and NTC8685 after *in vitro* EP were determined in human dendritic cells (DC) versus a CMV promoter comparator ([Supplementary Figure S4](#MOESM13){ref-type="media"}). All three NTC CMV-HTLV-I R promoter vectors had improved expression compared with a CMV promoter vector. In this system, in which isolated dividing cells are subjected to *in vitro* EP, a strong effect of the NTC8485 and NTC8685 encoding VA1 RNA or SV40 enhancer was not observed, although NTC8685 was the highest expressing vector in all three donors. This would indicate that cell stress was not induced by these *in vitro* conditions, and cell division eliminated the need for SV40-mediated nuclear entry (as reported in Li *et al.*^[@CR31]^).

### Other nuclear import binding proteins {#Sec10}

NF-κB and NM23-H2 nuclear shuttle protein binding sites increase plasmid nuclear localization when added to base vectors.^[@CR37],\ [@CR38]^ The SP1 protein is speculated to be a chromatin modulator that functions to maintain expression-competent euchromatin through association with histone acetyl transferases.^[@CR39]^ The SP1 and NM23-H2 sites also form a G-quadruplex (G4) structure. This is a local single-stranded DNA region, with a single-stranded three-loop structure formed by interactions with four 3-guanine motifs and three linking loops. G4 structures exclude nucleosomes and are recognized by a variety of DNA binding enzymes^[@CR40]^ that may function as nuclear shuttle proteins.

Binding sites for these proteins were integrated into the NTC8685 backbone. NTC8685 expression in dividing or non-dividing (aphidicolin treated) A549 was not improved by inclusion of DNA binding sequences for nuclear localizing proteins NF-κB (κβ), NM23-H2 (G4) or SP1 ([Figures 5e and f](#Fig5){ref-type="fig"}). A549 is known to express NM23-H2.^[@CR40]^ However, expression of NTC8385, NTC8485 and NTC8685 base vectors in aphidicolin-treated non-dividing A549 ([Figure 5f](#Fig5){ref-type="fig"}) and non-dividing HEK293 ([Figure 5d](#Fig5){ref-type="fig"}) cells was much higher than that of the gWIZ comparator. All these vectors were produced in *dcm*− hosts; hence, differences in expression levels could not be attributed to effects of plasmid *dcm* methylation. This implies that nuclear localization was optimal in these NTC backbones, and that inclusion of additional shuttle protein binding sites was redundant to existing nuclear localization signals present in these vectors.

Discussion {#Sec11}
==========

We report the development of regulatory-agency-compliant minimal AF DNA vaccine/gene therapy plasmid vectors that combined \>1 g l^−1^ fermentation yields^[@CR41]^ of high-quality plasmid with improved transgene expression by incorporation of TEE: (1) HTLV-I R; (2) adenoviral VA RNAI (VA1); and/or (3) SV40 72 and 21 bp repeats. These transient expression enhancers were non-coding sequences with no homology to the human genome. The expression-enhancing effects were limited to transiently transfected plasmids; no transgene expression enhancement was observed from integrated vector. Unlike matrix-attachment site vectors, TEE sequences did not increase the frequency of genome integration (Williams *et al.* manuscript in preparation). A vector family, incorporating various TEE combinations, is now available, allowing researchers to select the optimal combination for their application. TEE vectors could also be adapted to improve expression in specific cell types, through swapping of an alternative tissue-specific cellular promoter for the ubiquitous CMV promoter.

Three transient expression-augmenting sequences were identified and incorporated into minimal AF vectors in order to increase the *in vivo* expression of encoded transgenes. The HTLV-I R region, inserted downstream of the CMV promoter, dramatically increased transgene expression by enhancing mRNA translation efficiency. A similar and additive mRNA translation efficiency increase was observed with plasmid vectors further incorporating and expressing the protein kinase R (PKR)-inhibiting adenoviral VA RNAI (VA1). Finally, the SV40 enhancer, cloned upstream of the CMV enhancer, increased transgene expression in non-dividing cells. Importantly, these vectors did not increase transgene expression from plasmid DNA after forced genomic integration.

This phenomenon of translation stimulation restriction to extrachromosomal vector-derived mRNAs has been previously observed with VA1,^[@CR42]^ and was attributed to localized activation of PKR leading to translation inhibition through eukaryotic initiation factor-2α phosphorylation.^[@CR42],\ [@CR43]^ The similar *cis*-acting effect of HTLV-I R to enhance transient but not integrated plasmid mRNA translation is mechanistically distinct, because HTLV-I R and VA1 effects were additive. A critical difference between transient and genomically produced RNA is that transient mRNA is inefficiently translated ([Figure 2c](#Fig2){ref-type="fig"}). This may be due to aberrant mRNA splicing, differential cytoplasmic mRNA localization, altered stability of ribosome bound-RNA or differences in ribosome loading/composition/stability with transient compared with genomic source mRNA. The fragment of HTLV-I R incorporated into the 5′ UTR may alleviate these transient RNA-restricted effects.

Incorporation of DNA binding sites for nuclear shuttling proteins NF-κB and NM23-H2 into the NTC8685 vector backbone did not result in improved nuclear localization. Previous studies with these factors were with less-optimal vectors.^[@CR37],\ [@CR38],\ [@CR44]^ Nuclear localization capacity may be maximized with the extensively optimized minimalized NTC8685 vector.

The vector platform described herein, when combined with advanced delivery methods such as EP, further increased gene expression. This led to improved HIV-1 gp120 neutralizing antibody titers in rabbits after EP-mediated delivery of an HTLV-I R TEE vector. The reduced size compared with alternative vectors may be critical to improving gene transfer with large transgenes such as dystrophin, as large vectors have reduced transfection efficiency with EP delivery.^[@CR45]^ TEE vectors therefore have application to generally improve DNA vaccination or gene therapy. These improvements may be critical to enable future gene medicine licensure for public health applications.

Materials and methods {#Sec12}
=====================

Strains and plasmids {#Sec13}
--------------------

Vectors were constructed using standard molecular biology methods.^[@CR46]^ Plasmids NTC8385, NTC8485 and NTC8685 contain a 140 bp *Dra*III-*Kpn*I RNA-based sucrose selectable marker (RNA-OUT). NTC8485 and NTC8685 incorporate the high copy number PAS-BH-SV40 backbone from the kanR vector NTC7485.^[@CR6]^ NTC8485-κB and NTC8685-κB contain three copies of an optimized NF-κB binding site (underlined^[@CR44]^) inserted into the *Not*I site (bold) ([Figure 1c](#Fig1){ref-type="fig"}). NTC8685-κB 5′-GCGGCC[GGGACTTTCC]{.ul}AGCTG[GGGACTTTCC]{.ul}AGCTG[GGGACTTTCC]{.ul}**GCGGCCGC**-3′. NTC8685-2x SP1 contains two copies of an optimized SP1 transcription factor binding site (underlined^[@CR47]^) inserted between the *Not*I and *Nhe*I sites (bold) of the vector:2x SP1: 5′-**GCGGCCGC**TAGA[CGGGGCGGGGGC]{.ul}TCGA[CGGGGCGGGG]{.ul}**[GC]{.ul}TAGC**-3′. NTC8685-G4 contains one copy of the C-myc NM23-H2 transcription factor binding site (underlined^[@CR38]^) inserted between the *Not*I and *Nhe*I sites (bolded) of the vector: G4: 5′-**GCGGCCGC**TAGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGA**GCTAGC**-3′.

kanR plasmids were grown in either *Escherichia coli* strain *coli* DH5α (F-φ80d*lac*ZΔM15 Δ(*lac*ZYA -*arg*F) U169 *rec*A1 *end*A1 *hsd*R17 (rK−, mK+) *pho*A *sup*E44 λ-*thi*-1 *gyr*A96 *rel*A1) or *dcm*− version NTC48107 DH5α *dcm*, whereas AF plasmids were grown in either *dcm*+ NTC4862 (DH5α attλ::P5/6 6/6-RNA-IN-*SacB*, Cm^R^) or *dcm*− NTC48165 (DH5α *dcm* att~λ~::P~5/6\ 6/6~-RNA-IN- *SacB*, Cm^R^). For cell culture and immunization testing, low endotoxin (\<100 EU mg^−1^) plasmid DNA was purified using Nucleobond AX 2000 or AX 10 000 columns (Macherey Nagel, Düren, Germany). Where indicated, plasmid DNA was linearized by restriction enzyme digestion before transfection. Linearized plasmid DNA was purified by phenol/chloroform extraction and ethanol precipitation before being resuspended in TE buffer (10 m[M]{.smallcaps} Tris, 1 m[M]{.smallcaps} EDTA, pH 8.0) for transfection.

Cell culture {#Sec14}
------------

Adherent HEK293 (human embryonic kidney), A549 (human lung carcinoma), NIH3T3 (murine embryonic fibroblast), L929 (murine areolar fibroblast) and CHO-K1 (Chinese Hamster Ovary) cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). Cell lines were propagated in Dulbecco\'s modified Eagle\'s medium/F12 containing 10% fetal bovine serum and split (0.25% trypsin-EDTA) using Invitrogen (Carlsbad, CA, USA) reagents and conventional methodologies. For transfections, cells were plated on either 6- or 24-well tissue culture dishes. Supercoiled or linear plasmids were transfected into cell lines using Lipofectamine 2000 (or Lipofectamine LTX for CHO-K1) following the manufacturer\'s instructions (Invitrogen) and analyzed for duration and variability of expression in integrated (EGFP-IRES-neo transgene) and transient (EGFP transgene) expression systems as indicated. Plasmid integrants were selected using media containing 500 μg ml^−1^ Geneticin (Invitrogen) over 10 days. Total cellular lysates for EGFP determination were prepared by resuspending cells in cell lysis buffer (BD Biosciences Pharmingen, San Diego, CA, USA), lysing cells by incubating for 30 min at 37 °C, followed by a freeze--thaw cycle at −80 °C. Lysed cells were clarified by centrifugation and the supernatants assayed for EGFP by FLX800 microplate fluorescence reader (Bio-Tek, Winooski, VT, USA). Single cell suspensions for FACS flow cytometry were prepared by dissociating cells with trypsin treatment, and washing with media to remove trypsin and then phosphate-buffered saline for FACS analysis using the BD (Franklin Lakes, NJ, USA) FACSCalibur dual-laser cytometer.

Transfection of non-dividing cells was as described in Monkonge *et al.*^[@CR38]^ Briefly, HEK293 or A549 cells were pretreated overnight with 5 μg ml^−1^ aphidicolin (Sigma, St Louis, MO, USA), which inhibits cell division and synchronizes cells to early S phase. Transfection of EGFP plasmids and outgrowth were then performed in the presence of aphidicolin. Cell outgrowths were incubated with or without 25 ng ml^−1^ tumor necrosis factor-α (Invitrogen) for 3 h to induce NF-κB nuclear shuttling. Fresh medium was then added and total cell extracts were prepared for EGFP fluorescence determination 24 h (A549) or 48 h (HEK293) post transfection.

Real time (RT)-PCR (genomic DNA) {#Sec15}
--------------------------------

Genomic DNA was isolated from integrated cell lines using the DNeasy blood and tissue kit (Qiagen Sciences, Germantown, MD, USA) and total DNA was quantified using the FL × 800 microplate fluorescence reader (Bio-Tek) by determining picogreen (Invitrogen) fluorescence of samples versus a linearized vector standard curve. RT-PCR to quantify vector copies in genomic DNA was performed used a TaqMan EGFP transgene 6FAM-ACAGCCACAACTCT-MGBNFQ probe and flanking primers (5′-GGGCACAAGCTGGAGTACAAC-3′; 5′-TCTGCTTGTCGGCCATGATA-3′) in a TaqMan gene expression assay using Applied Biosystems (Foster City, CA, USA) TaqMan reagents and the Step One Real Time PCR System (Applied Biosystems, Carlsbad, CA, USA). Linearized vector was used for the RT-PCR standard curve.

Reverse transcriptase (RT)-PCR (cytoplasmic RNA) {#Sec16}
------------------------------------------------

Cytoplasmic RNA was isolated from transfected HEK293 cells using the protein and RNA isolation system (PARIS kit, Ambion, Austin TX, USA) and quantified by A~260~. Samples were DNase treated (DNA-free DNase; Ambion) before reverse transcriptase RT-PCR using the Agpath-ID One step RT-PCR kit (Ambion) and the EGFP transgene specific probe. DNase treatment was confirmed by the lack of detectable signal in control RT-PCR reactions run without the initial 48 °C reverse transcriptase step using heat-treated 25 × PCR buffer. Heat treatment inactivates heat-labile reverse transcriptase but not Taq DNA polymerase. Assay linearity was verified using sample dilutions.

Rabbit immunization {#Sec17}
-------------------

The HIV-1 gp120 envelope glycoprotein gene from the JRCSF strain was cloned into the pMAmp and AF NTC8382 backbones. The pMAmp plasmid has been described previously^[@CR48]^ and contains the CMV promoter and intron 1 for gene expression and the bovine growth hormone polyadenylation site. NTC8382 is the NTC8385 vector modified to secrete transgene using a tissue plasminogen activator secretion leader.^[@CR4]^ Both vectors express the identical tissue plasminogen activator--gp120 fusion protein. Each plasmid was injected into rabbits (six per group) on days 0, 28 and 56, followed by EP with the MedPulser electroporation system (Inovio Biomedical, San Diego, CA, USA). All rabbits were bled on days 42 and 70. On day 84, the rabbits received a booster injection of alum-adjuvanted gp120 protein. Rabbits were bled on day 98 and the study was terminated. Sera were prepared from the day 70 and 98 blood samples for measurement of the levels of HIV-1 neutralization activity. Neutralization was tested on two neutralization-sensitive viruses (SF162 and NL4-3) and two resistant viruses (6535 and JRCSF). Rabbit EP and virus neutralization assays were as described.^[@CR48]^ This animal study was conducted at Aldevron (Fargo, ND, USA) and was approved by Aldevron\'s Institutional Review Board.

Human DC EP {#Sec18}
-----------

DCs from three independent donors were generated as previously described^[@CR49]^ and nucleofected 24 h after maturation using the Amaxa DC nucleofection kit (Amaxa, Koeln, Germany). A total of 0.5--1 × 10^6^ DCs were prepared as per manufacturer\'s instructions, nucleofected with 2 μg of plasmid DNA and subsequently resuspended in complete RPMI media (10% fetal bovine serum, 2 mmol l^−1^ GlutaMAX and 1 mmol l^−1^ sodium pyruvate (Sigma)), supplemented with the cytokine maturation cocktail containing 10 ng ml^−1^ interleukin-1β, 10 ng ml^−1^ tumor necrosis factor-α, 100 ng ml^−1^ interleukin-6 (R&D Systems, Minneapolis, MN, USA), 1 μg ml^−1^ prostaglandin E2 (Sigma), 800 U ml^−1^ granulocyte macrophage colony-stimulating factor (Sargramostim Leukine; Immunex, Seattle, WA, USA) and 1000 U ml^−1^ interleukin-4 (R&D Systems). Nucleofection efficiency and EGFP transgene expression were assessed 18 h after nucleofection using the BD FACSCalibur flow cytometer. The data were analyzed using Cell Quest software (BD).
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